U.S. Animal Model Market

U.S. Animal model Market Outlook—2022-2032

[155 Pages] The demand in the U.S. animal model is set to increase at a 4.1% CAGR from 2022 to 2032, with the market valuation reaching around US$ 947.3 Mn in 2022. According to a recent study by Future Market Insights, mice held a substantial share of over 62.0% in 2021 within the U.S. market.

Animal model plays a valuable role in clinical research for the development of new drugs and treatments. Almost 90% of the processes for the development of drugs are depended on the testing of animal models.

Noticeable similarities, such as anatomical and physiological similarities, in humans and animals make animal models essential for biological research and drug development. Furthermore, growing need for novel drugs and customized medicines will boost the demand for animal models for clinical studies.

Rising trend of genetically modified animal models, such as genetically engineered mice (transgenic, knockout, knock-in, humanized) for the study of genetic diseases, multifactorial and polygenic (complex) disorders, neurodegenerative diseases, inflammatory diseases, and is boosting the growth in the market.

In 2021, the U.S. animal model held nearly 60% of the global animal model market worth US$ 1.5 Bn.

Sales Analysis of U.S. Animal Model from 2017 to 2021 Vs Market Outlook for 2022 to 2032

Demand in the U.S. animal model market increased at a 3% CAGR between 2017 to 2021. As per the report, sales are projected to grow at a 4.1% CAGR over the forecast period, on the back of surging demand for animal model for regenerative medicine and tissue engineering.

The presence and dominance of CROs in the country, which involve animal models in their research, and increasing focus on personalized medications are key factors expected to drive demand in the U.S.

Report Brochure

Due to the advent of COVID-19, people are giving priority to being fully vaccinated. With increasing vaccinations rates and rising awareness, demand for clinical research and studies is increasing. This has a direct impact on the demand for animal model as it is used in the development of various vaccines.

Further, ongoing research and development in the healthcare sector for the development of  regenerative medicine and tissue engineering are propelling demand for animal model. Growing usage of animal model-based preclinical interpretation of new therapeutics and drug discovery & development will fuel sales in the market.

What are the Key Opportunities for U.S. Animal Model Manufacturers?

Animal models are effective tools for conducting preclinical studies to learn more about human biology. The need to understand how drugs work in humans, as well as growing interest in investigating human-specific diseases, therapies, and immune responses, are driving the development and usage of animal models.

Increasing prevalence of diseases is compelling the government to focus on preventive measures. This is driving investments for performing clinical trials on animal models. For instance, in March 2020, the FDA spent around US$ 250,000 on the testing of coronavirus on animal models including monkeys, mice, ferrets, and others.

Hefty investments and policy reforms by the government have stimulated funding schemes with regard to animal model research, which is creating opportunities for growth in the market.

In addition to this, different species of animal models have different anatomy, physiology, lifespan, and disease characteristics. Therefore, some experiments on animals do not provide conclusive information on patient outcomes. For accurate clinical research in the discovery of drugs, there is still a need for perfect genetically modified animal models.

Animal model providers are benefitting from the next-generation sequencing technology and genome engineering tools to provide custom and rare disease models, with a focus on supporting personalized therapy drug trials.

For instance, Charles River Laboratories provides hACE2-NCG mouse models specifically designed for COVID-19 research. Such developments are expected to bode well for the market over the forecast period.

What are the Factors Restraining Demand in the U.S. Animal Model Market?

Delay in drug approvals and reduced possibilities of medication for human use can hamper the growth of the animal model market. Drugs that survive clinical trials and get approved are sometimes recalled because of toxicity identified in them after a few months or years.

Some animal models have limited ability to mimic proper complex processes of human physiology, progression, and carcinogenesis. Due to this, safety and efficacy identified in animal studies sometimes cannot be considered for humans. In many cases, certain mouse models’ physiological changes occur in the spectrum that do not occur in the human disease.

Additionally, some animal model tests take months or years to conduct and analyse. For example, approximately 4-5 years are taken for rodent cancer studies, which involves thousands and sometimes millions of dollars.

Due to the high costs of animal model clinical trials, government regulatory agencies and scientific organizations are finding alternative methods to replace animal testing and provide improvements in the safety of new medications for human use. This can hamper the growth of the animal model market.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Category-wise Insights

Which Species is Driving Sales?

“Demand in the Mice Model Segment Will Gain Momentum”

In terms of species, total sales in the mice model segment are expected to hold a market share value of around 62.6% in 2022, with sales growing at a 5.1% over the forecast period.

Mice models are one of the most important tools for performing preclinical research to acquire insights into human biology as they are genetically similar to humans. These models are created by engrafting human cells or tissues into mice, resulting in the expression of human proteins.

Mice are increasingly being employed as models in biomedical research for HIV/AIDS, cancer, regenerative medicine, hepatitis, and infectious disease research. They are being developed and used in response to a growing need to determine the true effects of medications on humans.

Besides this, growing focus on researching human-specific infections, therapies, and immunological responses will continue pushing sales in this segment in the forthcoming years.

Which is the Leading Therapeutics Segment in the Animal Model Market?

“Sales of Animal Models for Oncology Research to Remain High”

Based on therapeutics, the oncology segment held nearly 32.6% of the total market share in 2021, and the trend is expected to continue over the forecast period. Animal models are widely used in oncology to study the biochemical and physiological processes of the occurrence and development of cancer. They help in determining the most appropriate treatment approach for specific cancers.

Presently, there is a huge global burden of chronic diseases, including cancer. In vitro as well as in vivo approaches are being developed to fight against the rising prevalence of cancer. One of the most significant advancements is the development of humanized mouse and rodent models, as they offer high prescient power for the viability of standard and novel anti-cancer therapeutics.

Factors such as the importance of personalized medicine, monoclonal antibodies and the potential to treat diseases easily on a personal level are expected to fuel sales in this segment.

Which Application Holds a Dominant Share in the U.S. Animal Model Market?

“Adoption of Animal Models in Novel Drug Discovery will Continue Increasing”

By application, total sales of animal model in the drug discovery/development segment accounted for 65.4% of the total market share in 2021. Drug discovery/development is invariably a lengthy and costly process. It begins with the identification and validation of a potential molecular/cellular therapeutic target, and moves through a series of preclinical and clinical trials, culminating in a series of regulatory approvals. The usage of experimental animal models helps researchers better understand the genesis, pathophysiology, and overall character of human diseases.

Animal models for drug discovery and development have played a crucial role in the characterization of disease pathophysiology and associated mechanisms of injury and target identification.

They are also used for the evaluation of novel therapeutic agents for toxicity/safety, pharmacodynamics, pharmacokinetics, and efficacy for the development of safe and effective therapies and cures for diseases and/or symptoms connected with them.

Which End User Benefits the Most by the Employment of Animal Model?

“Applications of Animal Model in Academic and Research Institutes Will Gain Traction”

Based on end user, demand in the academic & research institutes segment more than 36.6% of the total market share in 2021. Growth can be attributed to increasing establishments of academic & research institutes in the country for the development of drugs and vaccines for various chronic diseases. Researchers utilize animal models to examine and assemble evidence-based findings to address different health-related problems.

Furthermore, the availability of highly qualified and skilled scientists at academic & research institutes will also contribute to the growth in this segment.  

Competitive Landscape

The U.S. animal model market is fragmented with the presence of established as well emerging market players. These players are actively investing in acquisitions, collaborations, and product launches as key strategies. For instance:

• In January 2022, Taconic Biosciences launched huNOG-EXL EA (Early Access) humanized immune system mouse. This unique mouse model supports human myeloid and lymphoid cells, which makes this mice model useful for immunological and oncological research.
• In April 2021, Ingenious Targeting Laboratory and SMOC collaborated to produce and distribute catalogue mouse models for Ingenious Targeting Laboratory to distribute SMOC’s validated off-the-shelf mouse models in North America and Europe.
• In June 2021, the  Dana-Farber Cancer Institute and Harbour BioMed collaborated to work on novel biotherapies for cancer treatment. Both organizations worked together on the development of CAR-T cell products and biospecific antibodies.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Report Scope as per U.S. Animal model Industry Analysis